Potential participants must not meet any of the following: <br/ >1. Currently treated with an ACEI, ARB or aldosterone antagonist, aliskiren, or angiotensin receptor neprilysin inhibitors (ARNi) <br/ >2.Serum potassium >5.2 mmol/L or no potassium testing within the last 3 months <br/ >3. Estimated Glomerular Filtration Rate (eGFR) less than 30ml/min/1.73m2 or no eGFR testing within the last 3 months, or <br/ >4. Known symptomatic postural hypotension <br/ >5. Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score 10-15) <br/ >6. Intolerance of ARB <br/ >7. Women <51 years who are pregnant, have a positive bHCG or are currently breastfeeding <br/ >8. Individuals who are not able to take medications by mouth at enrolment, or who are not expected to be able to take medications by mouth during the first 48 hours after randomisation <br/ >

Potential participants must not meet any of the following: <br/ >1. Currently treated with an ACEI, ARB or aldosterone antagonist, aliskiren, or angiotensin receptor neprilysin inhibitors (ARNi) <br/ >2.Serum potassium >5.2 mmol/L or no potassium testing within the last 3 months <br/ >3. Estimated Glomerular Filtration Rate (eGFR) less than 30ml/min/1.73m2 or no eGFR testing within the last 3 months, or <br/ >4. Known symptomatic postural hypotension <br/ >5. Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score 10-15) <br/ >6. Intolerance of ARB <br/ >7. Women <51 years who are pregnant, have a positive bHCG or are currently breastfeeding <br/ >8. Individuals who are not able to take medications by mouth at enrolment, or who are not expected to be able to take medications by mouth during the first 48 hours after randomisation <br/ >

N/A

N/A

Potential participants must not meet any of the following: <br/ >1. Currently treated with an ACEI, ARB or aldosterone antagonist, aliskiren, or angiotensin receptor neprilysin inhibitors (ARNi) <br/ >2.Serum potassium >5.2 mmol/L or no potassium testing within the last 3 months <br/ >3. Estimated Glomerular Filtration Rate (eGFR) less than 30ml/min/1.73m2 or no eGFR testing within the last 3 months, or <br/ >4. Known symptomatic postural hypotension <br/ >5. Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score 10-15) <br/ >6. Intolerance of ARB <br/ >7. Women <51 years who are pregnant, have a positive bHCG or are currently breastfeeding <br/ >8. Individuals who are not able to take medications by mouth at enrolment, or who are not expected to be able to take medications by mouth during the first 48 hours after randomisation <br/ >

Potential participants must not meet any of the following: <br/ >1. Currently treated with an ACEI, ARB or aldosterone antagonist, aliskiren, or angiotensin receptor neprilysin inhibitors (ARNi) <br/ >2.Serum potassium >5.2 mmol/L or no potassium testing within the last 3 months <br/ >3. Estimated Glomerular Filtration Rate (eGFR) less than 30ml/min/1.73m2 or no eGFR testing within the last 3 months, or <br/ >4. Known symptomatic postural hypotension <br/ >5. Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score 10-15) <br/ >6. Intolerance of ARB <br/ >7. Women <51 years who are pregnant, have a positive bHCG or are currently breastfeeding <br/ >8. Individuals who are not able to take medications by mouth at enrolment, or who are not expected to be able to take medications by mouth during the first 48 hours after randomisation <br/ >